In melanoma, aged patients often display impaired expansion of tumor‐specific CD8+ T cells following ICI therapy, accompanied by upregulation of exhaustion markers such as PD‐1, LAG‐3, and TIM‐3 [64]. This evidence concerns the gene HAVCR2 and melanoma.